FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre			ouer Name and Ticke S PHARMACI		-	,		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
O'NEIL PAT	RICK R.	131	DITIARWIACI	<u> </u>	CAI	<u> </u>	.313]		Director	10% (Owner		
(Last)	(First)	(Middle)	3 Da	te of Earliest Transac	ction (M	onth/[)av/Year)		X	Officer (give title below)	Other below	(specify)	
C/O ISIS PHARMACEUTICALS, INC.				3/2014			,,		SVP, Legal & General Counsel				
2855 GAZELLE COURT													
(Street)				Amendment, Date of	Original	Filed	(Month/Day/Y	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Applicable Line)				
CARLSBAD	CA	92010								Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)											
		Table I - No	n-Derivative	Securities Acq	uired,	Dis	posed of, o	or Ben	eficially	Owned			
Date			2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1115tt. 4)	
Common Stock			11/03/2014	11/03/2014	M ⁽¹⁾		1,500(1)	A	\$7.25	5,253	D		
Common Stock 11/03/				11/03/2014	S ⁽²⁾		1,500(2)	D	\$46.17	3,753	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to	\$7.25	11/03/2014	11/03/2014	М			1,500	01/03/2013 ⁽³⁾	01/02/2019	Common Stock	1,500	\$0	11,533	D	

Explanation of Responses:

- 1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 1/2/2014.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$45.71 to \$46.39, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- $3.\ Grant\ of\ 1/3/2012\ to\ reporting\ person\ of\ stock\ options\ under\ the\ Isis\ Pharmacueticals,\ Inc.\ 1989\ Stock\ Option\ Plan.\ 25\%\ of\ the\ shares\ subject\ to\ the\ option\ vested\ and\ became\ exercisable\ on\ 1/3/2013.$ Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 4,875 shares per year. Following this transaction, the option was exercisable as to 5,845 on 11/3/2014.

Remarks:

/s/Patrick R. O'Neil

11/05/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.